Development of a transmucosal technique for erythromycin delivery to treat gastroparesis

Ryan Mclemore, Brian Lunt, Sarah Salameh, John K. Dibaise, Michael D. Crowell, Brent L. Vernon

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Gastroparesis is a serious condition that limits meal or medication emptying from the stomach, resulting in a variety of symptoms, altered nutrition, and inconsistent medication delivery. Our aim was to develop a transmucosal system to deliver erythromycin (EM), a gastric prokinetic agent, to bypass intestinal absorption. Humans and Sprague-Dawley rats were given EM by injection, gavage, or transmucosal gel with or without permeation enhancers. Pharmacokinetics were compared between subjects and across different delivery modalities. Drug concentrations in blood were measured using a bioassay. Design of Experiment techniques were used to optimize transmucosal antibiotic delivery in the Sprague-Dawley Model. Finally, we examined the scale-up of transmucosal delivery to human patients. Transmucosal delivery of EM increased with addition of ursodeoxycholate. While EM release from gels with ursodeoxycholate was significant, it was less than by injection. Scale-up to a human model indicated that delivery of EM using this transmucosal delivery system is insufficient for clinical need. The transport of EM seems limited by its solubility in water and thickness of the epithelial cell layers. Providing successful transmucosal delivery of EM and similar molecules to humans will require more aggressive techniques to disrupt the cellular layer, or pro-drug strategies to increase lipid solubility.

Original languageEnglish (US)
Pages (from-to)2905-2913
Number of pages9
JournalJournal of Pharmaceutical Sciences
Volume99
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Gastroparesis
Erythromycin
Solubility
Gels
Gastrointestinal Agents
Injections
Intestinal Absorption
Prodrugs
Biological Assay
Sprague Dawley Rats
Meals
Stomach
Pharmacokinetics
Epithelial Cells
Anti-Bacterial Agents
Lipids
Water

Keywords

  • Bioassay
  • Carbopol/carbomer
  • Oral (buccal) mucosa
  • Permeation enhancer
  • Pharmacokinetics
  • Sprague-dawley rat

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Mclemore, R., Lunt, B., Salameh, S., Dibaise, J. K., Crowell, M. D., & Vernon, B. L. (2010). Development of a transmucosal technique for erythromycin delivery to treat gastroparesis. Journal of Pharmaceutical Sciences, 99(6), 2905-2913. https://doi.org/10.1002/jps.22037

Development of a transmucosal technique for erythromycin delivery to treat gastroparesis. / Mclemore, Ryan; Lunt, Brian; Salameh, Sarah; Dibaise, John K.; Crowell, Michael D.; Vernon, Brent L.

In: Journal of Pharmaceutical Sciences, Vol. 99, No. 6, 06.2010, p. 2905-2913.

Research output: Contribution to journalArticle

Mclemore, R, Lunt, B, Salameh, S, Dibaise, JK, Crowell, MD & Vernon, BL 2010, 'Development of a transmucosal technique for erythromycin delivery to treat gastroparesis', Journal of Pharmaceutical Sciences, vol. 99, no. 6, pp. 2905-2913. https://doi.org/10.1002/jps.22037
Mclemore, Ryan ; Lunt, Brian ; Salameh, Sarah ; Dibaise, John K. ; Crowell, Michael D. ; Vernon, Brent L. / Development of a transmucosal technique for erythromycin delivery to treat gastroparesis. In: Journal of Pharmaceutical Sciences. 2010 ; Vol. 99, No. 6. pp. 2905-2913.
@article{1141fc2e19be488e9656a985f7b06977,
title = "Development of a transmucosal technique for erythromycin delivery to treat gastroparesis",
abstract = "Gastroparesis is a serious condition that limits meal or medication emptying from the stomach, resulting in a variety of symptoms, altered nutrition, and inconsistent medication delivery. Our aim was to develop a transmucosal system to deliver erythromycin (EM), a gastric prokinetic agent, to bypass intestinal absorption. Humans and Sprague-Dawley rats were given EM by injection, gavage, or transmucosal gel with or without permeation enhancers. Pharmacokinetics were compared between subjects and across different delivery modalities. Drug concentrations in blood were measured using a bioassay. Design of Experiment techniques were used to optimize transmucosal antibiotic delivery in the Sprague-Dawley Model. Finally, we examined the scale-up of transmucosal delivery to human patients. Transmucosal delivery of EM increased with addition of ursodeoxycholate. While EM release from gels with ursodeoxycholate was significant, it was less than by injection. Scale-up to a human model indicated that delivery of EM using this transmucosal delivery system is insufficient for clinical need. The transport of EM seems limited by its solubility in water and thickness of the epithelial cell layers. Providing successful transmucosal delivery of EM and similar molecules to humans will require more aggressive techniques to disrupt the cellular layer, or pro-drug strategies to increase lipid solubility.",
keywords = "Bioassay, Carbopol/carbomer, Oral (buccal) mucosa, Permeation enhancer, Pharmacokinetics, Sprague-dawley rat",
author = "Ryan Mclemore and Brian Lunt and Sarah Salameh and Dibaise, {John K.} and Crowell, {Michael D.} and Vernon, {Brent L.}",
year = "2010",
month = "6",
doi = "10.1002/jps.22037",
language = "English (US)",
volume = "99",
pages = "2905--2913",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Development of a transmucosal technique for erythromycin delivery to treat gastroparesis

AU - Mclemore, Ryan

AU - Lunt, Brian

AU - Salameh, Sarah

AU - Dibaise, John K.

AU - Crowell, Michael D.

AU - Vernon, Brent L.

PY - 2010/6

Y1 - 2010/6

N2 - Gastroparesis is a serious condition that limits meal or medication emptying from the stomach, resulting in a variety of symptoms, altered nutrition, and inconsistent medication delivery. Our aim was to develop a transmucosal system to deliver erythromycin (EM), a gastric prokinetic agent, to bypass intestinal absorption. Humans and Sprague-Dawley rats were given EM by injection, gavage, or transmucosal gel with or without permeation enhancers. Pharmacokinetics were compared between subjects and across different delivery modalities. Drug concentrations in blood were measured using a bioassay. Design of Experiment techniques were used to optimize transmucosal antibiotic delivery in the Sprague-Dawley Model. Finally, we examined the scale-up of transmucosal delivery to human patients. Transmucosal delivery of EM increased with addition of ursodeoxycholate. While EM release from gels with ursodeoxycholate was significant, it was less than by injection. Scale-up to a human model indicated that delivery of EM using this transmucosal delivery system is insufficient for clinical need. The transport of EM seems limited by its solubility in water and thickness of the epithelial cell layers. Providing successful transmucosal delivery of EM and similar molecules to humans will require more aggressive techniques to disrupt the cellular layer, or pro-drug strategies to increase lipid solubility.

AB - Gastroparesis is a serious condition that limits meal or medication emptying from the stomach, resulting in a variety of symptoms, altered nutrition, and inconsistent medication delivery. Our aim was to develop a transmucosal system to deliver erythromycin (EM), a gastric prokinetic agent, to bypass intestinal absorption. Humans and Sprague-Dawley rats were given EM by injection, gavage, or transmucosal gel with or without permeation enhancers. Pharmacokinetics were compared between subjects and across different delivery modalities. Drug concentrations in blood were measured using a bioassay. Design of Experiment techniques were used to optimize transmucosal antibiotic delivery in the Sprague-Dawley Model. Finally, we examined the scale-up of transmucosal delivery to human patients. Transmucosal delivery of EM increased with addition of ursodeoxycholate. While EM release from gels with ursodeoxycholate was significant, it was less than by injection. Scale-up to a human model indicated that delivery of EM using this transmucosal delivery system is insufficient for clinical need. The transport of EM seems limited by its solubility in water and thickness of the epithelial cell layers. Providing successful transmucosal delivery of EM and similar molecules to humans will require more aggressive techniques to disrupt the cellular layer, or pro-drug strategies to increase lipid solubility.

KW - Bioassay

KW - Carbopol/carbomer

KW - Oral (buccal) mucosa

KW - Permeation enhancer

KW - Pharmacokinetics

KW - Sprague-dawley rat

UR - http://www.scopus.com/inward/record.url?scp=77951584073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951584073&partnerID=8YFLogxK

U2 - 10.1002/jps.22037

DO - 10.1002/jps.22037

M3 - Article

C2 - 20039386

AN - SCOPUS:77951584073

VL - 99

SP - 2905

EP - 2913

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 6

ER -